European Patent Office Issues Three New Patents For Suven Life Sciences

Suven Life Sciences has secured three patents EP1537113, EP1704154 and EP1856132 issued by European Patent Office (EPO).These patents corresponds to three New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2022, 23 and 24 respectively.

The company said that granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzeimer’s, parkinson, schizophreneria and huntington’s diseases.

With these new patents, Suven has total of 7 granted patents on NCEs. All the 7 EPO patents have been validated in the 37 member countries of Europe. These granted patents are intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out licensed at various stages of clinical development like at Phase-1 or Phase-2.

Venkat Jasti, CEO of Suven, said: “We are pleased by the grant of these Patents to Suven by EPO for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20 billion market potential globally.”